Emicizumab prophylaxis for patients with haemophilia A

Blood and Immune System

1 July 2022

Published on 01 Jul 2022
Last Updated on 01 Jul 2022

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended listing emicizumab on the Medication Assistance Fund (MAF) in line with its registered indication as prophylaxis for patients with haemophilia A with or without factor VIII inhibitors to prevent or reduce bleeding episodes, due to unfavourable cost-effectiveness compared with subsidised alternatives at the price proposed by the manufacturer.

Emicizumab prophylaxis for patients with haemophilia A (1 Jul 22) [PDF, 130 KB]

Emicizumab prophylaxis for patients with haemophilia A PES (1 Jul 22) [PDF, 115 KB]